Medical/Pharmaceuticals

Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D

SHANGHAI and HONG KONG, Aug. 24, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...

2026-08-24 09:00 2182

Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion

TAIPEI, Aug. 24, 2026 /PRNewswire/ -- Anbogen Therapeutics Inc. (TPEx: 7784) ("Anbogen" or the "Company"), a clinical-stage precision oncology company, today announced that it has entered into a Collaborative Research Agreement (CRA) with the Laboratory of Veterinary Surgery, Graduate School of ...

2026-08-24 08:00 1333

Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation

SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- On August 21, Henlius (2696.HK) announced its interim results for the 2026 fiscal year. During the reporting period, the company showcased strong organic growth momentum and sustainable earnings generation, with revenue reaching RMB 3.5882 billion, a 27.3% ...

2026-08-21 21:50 17688

LumenStim Prepares to Launch Next-Generation Teeth Whitening System on Kickstarter

Kickstarter-approved LumenStim Teeth Whitening System brings peroxide-free whitening into daily brushing as the company advances global patent applications for its oral-care tec...

2026-08-21 21:00 2357

Coreline Soft and INFINITT North America Deploy Chest CT-Based AI Reading Workflow at St. Joseph's Health

PHILLIPSBURG, N.J. and ATLANTA, Aug. 21, 2026 /PRNewswire/ -- Coreline Soft,

2026-08-21 21:00 5065

CureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical Development of Novel Oral Liver-Targeting THR-β Agonist

SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist developed in-house, in Australia. Subject enrollment is progressing smoothly. CG-0416 is designed based o...

2026-08-21 20:08 16383

China's Personalized mRNA Cancer Therapy Sector Accelerates: How Far Is It From a "DeepSeek Moment"?

BEIJING, Aug. 21, 2026 /PRNewswire/ -- Personalized mRNA cancer therapy has recently reached an important milestone. An international Phase 3 study in high-risk melanoma reported positive results, further supporting the clinical potential of personalized neoantigen therapy and drawing renewed att...

2026-08-21 17:28 1611

Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy

NANJING, China, Aug. 21, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for Op...

2026-08-21 17:20 1904

Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026

SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that the latest clinical data on its novel epidermal growth factor receptor (EGFR) inhibitor ZE...

2026-08-21 16:03 1855

3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth

SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- 3S Bio (01530.HK) today announced its interim results for the first half of 2026. During the period, the Company recorded revenue of RMB 4.53 billion, representing a year-over-year growth of 3.9%. Net profit attributable to equity holders of the Company rea...

2026-08-21 15:39 4828

Sunshine Guojian Releases 2026 Interim Report:

Innovation-driven, Steady Advancement SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- Today, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (hereinafter referred to as "Sunshine Guojian", stock code: 688336.SH), a pioneer in China's antibody therapeutics, released its 2026 interim report. In the f...

2026-08-21 08:00 3677

Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results

Topline Data from Phase 2b Studies Inform HBV Functional Cure Strategy; Additional Data Expected in 2H 2026 Emerging Discovery Programs Build Momentum BRII-5395 mRNA Cancer Vaccine Moving into Clinical Evaluation for HCC Strong Cash Position Supports Continued Strategic Execution Conference Cal...

2026-08-21 07:10 3460

inFlow Inventory launches lot number and expiry date tracking

Small manufacturers and distributors in food, beverage, pharmaceutical and medical device industries can now trace any batch from receipt to customer, at a fraction of the cost of an enterprise ERP. TORONTO, Aug. 21, 2026 /PRNewswire/ -- inFlow Inventory has launched lot number and expiry date ...

2026-08-20 23:31 1806

Zylox-Tonbridge Delivers Strong First-Half 2026 Results as International Revenue Surges 349%

Revenue rose 31.1% to RMB 632 million, while net profit increased 47.8% to RMB 179 million HANGZHOU, China, Aug. 20, 2026 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190, "Zylox-Tonbridge" or the "Company") today announced its interim results for the six months ended Jun...

2026-08-20 23:10 1818

Apollo Hospitals launches 'Always Open, Always Here', a global first in healthcare from India

NEW DELHI, Aug. 20, 2026 /PRNewswire/ -- Apollo Hospitals launched 'Always Open. Always Here.', a first-of-its-kind initiative that makes routine and planned healthcare services available across all seven days of the week, including Sundays.

2026-08-20 22:11 1753

Matwings Demonstrates Closed-Loop Protein AI Through Four AI-Wet Lab Cycles and 222 Protein Variants

The GenSci148 program illustrates a shift from one-time mutation prediction to iterative protein engineering under real drug-development constraints SHANGHAI, Aug. 20, 2026 /PRNewswire/ -- Shanghai Matwings Technology Co., Ltd. ("Matwings") today announced that GenSci148 Injection, an investigati...

2026-08-20 19:00 1132

ISoOR 2026 Organoid Clinical Transformation Summit convened in Hangzhou

ICORE launched; nine companies joined as founding members HANGZHOU, China, Aug. 20, 2026 /PRNewswire/ -- On August 18, the International Society of Organoid Research (ISoOR) held its 2026 Organoid Clinical TransformationSummit in Hangzhou. Under the theme "From Biological Models to Credible Evid...

2026-08-20 13:08 1068

Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline

MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the period ended June 30, 2026. H1 2026 key results Group performance[1]: Double-digit revenue growth and gross margin imp...

2026-08-20 08:02 2633

Pillar Biosciences, LC-SCRUM-Asia and LSI Medience Announce Liquid Biopsy Screening Collaboration in Lung Cancer

oncoReveal® Essential+ validated at LSI Medience for cfDNA/cfRNA screening in the LC-SCRUM-Asia project, with testing planned to begin in August 2026 NATICK, Mass. and TOKYO, Aug. 20, 2026 /PRNewswire/ -- Pillar Biosciences, Inc. ("Pillar"), LC-SCRUM-Asia and LSI Medience Corporation ("LSI Medie...

2026-08-20 06:00 2009

XtalPi Holdings Announces 2026 Interim Results

SHENZHEN, China, Aug. 19, 2026 /PRNewswire/ --  Financial Highlights: * In the first half of 2026, the Group recorded revenue of RMB393.6 million, compared with RMB517.1 million in the corresponding period of last year. The change was primarily attributable to the high base in the correspondin...

2026-08-19 21:19 2264
1234567 ... 645